Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
Want to see ORMP full AI Analyst Report?
ORMP Stock Chart & Stats
$2.91
-$0.04(-1.65%)
At close: 4:00 PM EST
$2.91
-$0.04(-1.65%)
Day’s Range― - ―
52-Week Range$1.98 - $5.01
Previous CloseN/A
Volume63.61K
Average Volume (3M)210.74K
Market Cap
$158.79M
Enterprise Value$142.67M
Total Cash (Recent Filing)$65.84M
Total Debt (Recent Filing)$761.00K
Price to Earnings (P/E)1.4
Beta0.57
Next Earnings
Jul 15, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.65
Shares Outstanding40,926,083
10 Day Avg. Volume339,860
30 Day Avg. Volume210,739
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)59.00
P/FCF Ratio-10.65
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.18K
Enterprise Value/Ebitda1.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
InvestmentThe joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.
Joint VentureOramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.
Bears Say
Clinical EfficacyThe candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.
Oramed Pharm News
ORMP FAQ
What was Oramed Pharmaceuticals’s price range in the past 12 months?
Oramed Pharmaceuticals lowest stock price was $1.98 and its highest was $5.01 in the past 12 months.
What is Oramed Pharmaceuticals’s market cap?
Oramed Pharmaceuticals’s market cap is $158.79M.
When is Oramed Pharmaceuticals’s upcoming earnings report date?
Oramed Pharmaceuticals’s upcoming earnings report date is Jul 15, 2026 which is in 24 days.
How were Oramed Pharmaceuticals’s earnings last quarter?
Oramed Pharmaceuticals released its earnings results on Jan 08, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Oramed Pharmaceuticals overvalued?
According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued.
Does Oramed Pharmaceuticals pay dividends?
Oramed Pharmaceuticals pays a N/A dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Oramed Pharmaceuticals dividends here
What is Oramed Pharmaceuticals’s EPS estimate?
Oramed Pharmaceuticals’s EPS estimate is 0.43.
How many shares outstanding does Oramed Pharmaceuticals have?
Oramed Pharmaceuticals has 40,926,083 shares outstanding.
What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?
Oramed Pharmaceuticals reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 6.43%.
Which hedge fund is a major shareholder of Oramed Pharmaceuticals?
Currently, no hedge funds are holding shares in ORMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oramed Pharm Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.25%
12-Months-Change
Fundamentals
Return on Equity
55.29%
Trailing 12-Months
Asset Growth
82.22%
Trailing 12-Months
Company Description
Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Technical Analysis
―
Whitehawk Therapeutics
―
Quince Therapeutics
―
ALX Oncology Holdings
―
Spruce Biosciences
―
Ownership Overview
21.98% Insiders
0.31% Mutual Funds
22.41% Other Institutional Investors
54.62% Public Companies and
Individual Investors